Sosei Group has been granted a patent for compounds that act as agonists of the muscarinic M1 and M4 receptors. These compounds are designed for treating various conditions, including cognitive and psychotic disorders, pain, addiction, and movement disorders, through specific pharmaceutical compositions. GlobalData’s report on Sosei Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sosei Group, was a key innovation area identified from patents. Sosei Group's grant share as of July 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12024499B2 outlines a method for treating various disorders, including cognitive and psychotic disorders, as well as different types of pain such as acute, chronic, neuropathic, and inflammatory pain. The method involves administering an effective amount of a specific compound, denoted as formula (1). The claims specify that the compound can be modified by selecting R4 as either hydrogen or methyl, which may influence its therapeutic efficacy. Additionally, the patent lists several specific compounds that fall under this formula, including various ethyl derivatives of 6-azaspiro[3.4]octane-6-carboxylate, each featuring different substituents on the piperidine and azetidine moieties.
Furthermore, the patent claims that the compounds can be administered in the form of a pharmaceutical composition, which may include a pharmaceutically acceptable salt and excipients to enhance delivery and stability. The inclusion of these salts and excipients is intended to ensure that the compounds are suitable for therapeutic use. The claims also suggest that the method can be adapted to treat addiction and movement disorders, indicating a broad potential application for the compounds described. Overall, the patent provides a framework for the development of new therapeutic agents targeting a range of neurological and pain-related conditions.
To know more about GlobalData’s detailed insights on Sosei Group, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
